Why Reactive Security Is Failing—And What Comes Next
Monumental LLC Announces ‘Star Trek: Warp’ Collectible Card Game – Now Available to Wishlist on Steam
CampDoc Announces Integration with ACTIVE Network to Streamline Registration and Health Records for Camps and Youth Programs
CPAClub Approved to Perform CTAPP Compliance Reviews for California Attorneys
FLYR Powers Riyadh Air’s Debut as World’s First Full-Service Airline Built for Modern Retailing
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company”…
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect…
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders…
Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World’s…
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Silo Pharma Inc. (OTCQB:…
Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30…
Results anticipated in H2 2022 NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics…
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced…
The Company also Plans on Sharing INKmune™ Patient Case Studies Boca Raton, Florida, March 30,…
Ji’an, Jiangxi, China, March 30, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) — PepGen, Inc., advancing the next generation of oligonucleotide…
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses…
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be…
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had…
– First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory…
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening…
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray Brands” or the…
– Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments,…